NYSE:ABBVBiotechs
AbbVie (ABBV) One Off US$5.0b Loss Tests Bullish High P/E Valuation Narratives
AbbVie (ABBV) has wrapped up FY 2025 with fourth quarter revenue of US$16.6 billion and basic EPS of US$1.02, setting the tone for a year where trailing twelve month revenue reached US$61.2 billion alongside EPS of US$2.38. The company has seen revenue move from US$56.3 billion to US$61.2 billion on a trailing basis, while trailing EPS shifted from US$2.40 to US$2.38, giving investors a clear read on the top line against more compressed profitability. With a trailing net profit margin of 6.9%...